stoxline Quote Chart Rank Option Currency Glossary
Gamida Cell Ltd. (GMDA)
0.0327  -0.007 (-18.25%)    04-05 16:00
Open: 0.0395
High: 0.0395
Volume: 19,048,523
Pre. Close: 0.04
Low: 0.032
Market Cap: 4(M)
Technical analysis
2024-06-28 5:21:27 PM
Short term     
Mid term     
Targets 6-month :  0.04 1-year :  0.05
Resists First :  0.03 Second :  0.04
Pivot price 0.01
Supports First :  0.02 Second :  0
MAs MA(5) :  0.02 MA(20) :  0.01
MA(100) :  0.2 MA(250) :  0.72
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  72.2 D(3) :  67.1
RSI RSI(14): 50.8
52-week High :  2.5 Low :  0
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ GMDA ] has closed above the upper band by 12.4%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 84.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 29 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.04 - 0.04 0.04 - 0.04
Low: 0.03 - 0.03 0.03 - 0.03
Close: 0.03 - 0.03 0.03 - 0.03
Company Description

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. In addition, the company is developing NK cell pipeline comprising GDA-301, GDA-401, GDA-501, and GDA-601 to treat hematologic malignancies and solid tumors. The company was founded in 1998 and is headquartered in Jerusalem, Israel.

Headline News

Thu, 16 May 2024
Financial distress pushes key drug maker to Chapter 11 bankruptcy - TheStreet

Thu, 28 Mar 2024
Going private last option for Gamida Cell to remain as going concern - The Pharma Letter

Wed, 27 Mar 2024
Mister Car Wash CFO sells over $28k in company stock By -

Wed, 27 Mar 2024
Why Gamida Cell Shares Are Falling Today - Benzinga

Wed, 27 Mar 2024
Gamida Cell Ltd. Announces Strategic Restructuring and Privatization - TipRanks

Wed, 27 Mar 2024
Gamida Cell Announces Commencement of Restructuring Process Supported by Highbridge Capital Management - StockTitan

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out -54 (M)
Shares Float 0 (M)
Held by Insiders 1.3264e+008 (%)
Held by Institutions 1.2038e+008 (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.82
Profit Margin 0 %
Operating Margin -2 %
Return on Assets (ttm) 680.2 %
Return on Equity (ttm) -41.5 %
Qtrly Rev. Growth 103.7 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.58
Qtrly Earnings Growth -7.591e+007 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio 0
PEG Ratio 0
Price to Book value -0.04
Price to Sales 0
Price to Cash Flow 0
Stock Dividends
Dividend 9.98e+006
Forward Dividend 8.86e+006
Dividend Yield 30519900000%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android